Recruiting Breast Cancer Studies in Los Alamitos
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal G...
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TP...
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone rece...
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally adva...
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b pa...
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastas...
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab...
About Breast Cancer Clinical Trials in Los Alamitos
Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.
There are currently 7 breast cancer clinical trials recruiting participants in Los Alamitos, CALIFORNIA. These studies are seeking a combined 8,294 participants. Research is being sponsored by Stemline Therapeutics, Inc., Merck Sharp & Dohme LLC, Celcuity Inc and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Breast Cancer Clinical Trials in Los Alamitos — FAQ
Are there breast cancer clinical trials in Los Alamitos?
Yes, there are 7 breast cancer clinical trials currently recruiting in Los Alamitos, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Los Alamitos?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Los Alamitos research site will contact you about next steps.
Are clinical trials in Los Alamitos free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Los Alamitos studies also compensate for your time and travel.
What breast cancer treatments are being tested?
The 7 active trials in Los Alamitos are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.
Data updated March 2, 2026 from ClinicalTrials.gov